Ligand Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LGND | 6IB.F | ABCL | ROIV | 688382.SS | SMZ1.F | |
|---|---|---|---|---|---|---|
| Market cap | 6.32B | 17.27B | 3.98B | 27.61B | 8.38B | 11.09B |
| P/E (TTM) | 127.0 | 123.8 | — | — | — | 31.2 |
| Forward P/E | 25.9 | — | -16.1 | -27.5 | -43.8 | — |
| Price/book | 6.6 | 6.2 | 4.2 | 6.5 | 6.6 | 2.6 |
| Dividend yield | — | — | — | — | — | 2.90% |
| 1-year change | +51.82% | −1.76% | +171.08% | +85.85% | −48.70% | −23.60% |
| Today | +0.83% | +3.42% | +0.82% | +6.08% | +4.33% | +1.45% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LGND news ›Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Melanie Herman - Executive Director of Investor Relations and Financial Planning & AnalysisTodd Davis - CEO & DirectorOctavio Espinoza - Chief…
Ligand raises 2026 adjusted EPS guidance to $9.50-$9.75 while targeting ~$200M annual capital deployment
Ligand Q3 2026 earnings: royalty revenue jumped 51%, EPS guidance rose, and XOMA boosted growth. Earnings Call Insights: Ligand Pharmaceuticals (LGND) Q3 2026 - “The third quarter was an important one for Ligand with royalty revenue…
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million
Ligand Pharmaceuticals said Tuesday it has acquired a tiered royalty interest in Santen Pharmaceutical's Ryjunea from Sydnexis for an upfront payment of $23 million. Under the deal, Ligand said it... Ligand Pharmaceuticals Acquires Ryjunea…
Ligand Pharmaceuticals (LGND) Set to Announce Earnings on Thursday
Posted by Tristan Rich on Oct 22nd, 2026 Read Our Latest Stock Analysis on LGND The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active…
Head to Head Comparison: Ligand Pharmaceuticals (NASDAQ:LGND) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA)
Posted by Mitch Edgeman on Oct 19th, 2026 Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both mid-cap healthcare companies, but which is the superior…
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
GlobeNewswire 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026 The company will hold a conf
Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares of Company Stock
Andrew Reardon also recently made the following trade(s): View Our Latest Stock Analysis on Ligand Pharmaceuticals The company’s best-known technology is Captisol, a chemically modified cyclodextrin designed to improve the solubility,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com4
- themarketsdaily.com2
- defenseworld.net1
- globenewswire.com1
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.